Celltech Group plc (`Celltech') Cancellation of Listing
14 juil. 2004 07h17 HE
|
Celltech Group plc
SLOUGH, U.K., July 14, 2004 (PRIMEZONE) -- NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN OR INTO AUSTRALIA, BELGIUM, CANADA OR JAPAN
Celltech Group plc ("Celltech")
Cancellation of...
Celltech Announces U.S. FDA Approval For 12-Hour Codeprex
23 juin 2004 03h26 HE
|
Celltech Group plc
SLOUGH, U.K., June 23, 2004 (PRIMEZONE) -- Celltech Group plc (LSE:CCH) (NYSE:CLL) announces that the U.S. Food and Drug Administration ("FDA") has approved Codeprex(tm) (codeine polistirex/...
Celltech Group plc: Offer Document Posted
19 mai 2004 05h06 HE
|
Celltech Group plc
SLOUGH, U.K., May 19, 2004 (PRIMEZONE) -- NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN, INTO OR FROM BELGIUM, CANADA, AUSTRALIA OR JAPAN
UCB S.A.
...
Recommended Cash Offer For Celltech Group plc By UCB S.A.
18 mai 2004 03h02 HE
|
Celltech Group plc
Slough, U.K., May 18, 2004 (PRIMEZONE) -- Celltech Group plc
-- Celltech's shareholders to receive 550 pence per
ordinary share (equivalent to USD 19.44 per American
...
Celltech and UCB Reach Worldwide Agreement on Development and Marketing of CDP870
18 mai 2004 02h04 HE
|
Celltech Group plc
SLOUGH, U.K., May 18, 2004 (PRIMEZONE) -- Celltech Group plc (LSE:CCH)(NYSE:CLL) announces that it has entered into an agreement with UCB S.A. for the worldwide development and marketing of CDP870,...
Celltech Group plc Submits Xyrem for Approval in Europe
01 avr. 2004 01h02 HE
|
Celltech Group plc
SLOUGH, U.K., April 1, 2004 (PRIMEZONE) -- Celltech Group plc (LSE:CCH) (NYSE:CLL) today announces that the European Medicines Evaluation Agency (EMEA) has accepted for review its marketing...
Celltech Group plc Outlines Positive Preliminary Results From First CDP870 Phase III Trial In Rheumatoid Arthritis
31 mars 2004 02h01 HE
|
Celltech Group plc
SLOUGH, U.K., March 31, 2004 (PRIMEZONE) -- Celltech Group plc (LSE:CCH) (NYSE:CLL) today announces positive preliminary results from the first Phase III clinical trial with CDP870 in rheumatoid...
Celltech Group plc -- Preliminary Announcement Of Results For Year Ended 31 December 2003
16 mars 2004 02h02 HE
|
Celltech Group plc
SLOUGH, U.K., March 16, 2004 (PRIMEZONE) -- Celltech Group plc (LSE:CCH) (NYSE:CLL) today announces preliminary results for the year ended 31 December 2003. Results highlights are as follows:
--...
Celltech and Biogen Idec Announce Autoimmune Disease Collaboration
05 févr. 2004 02h01 HE
|
Celltech Group plc
SLOUGH, U.K., Feb. 5, 2004 (PRIMEZONE) -- Celltech Group plc (LSE:CCH) (NYSE:CLL) and Biogen Idec (Nasdaq:BIIB) announce that they have entered into a collaboration for the research, development and...
Celltech Achieves Further Milestone In Osteoporosis Collaboration With Amgen
08 janv. 2004 02h01 HE
|
Celltech Group plc
SLOUGH, U.K., Jan. 8, 2004 (PRIMEZONE) -- Celltech Group plc (LSE:CCH) (NYSE:CLL) today announces the achievement of a further milestone in its agreement with Amgen Inc. for the research, development...